KYEMPO

Serial Number 97619090
606

Registration Progress

Application Filed
Oct 4, 2022
Under Examination
Mar 21, 2023
Approved for Publication
Jan 24, 2023
Published for Opposition
Jan 24, 2023
Registered

Trademark Image

KYEMPO

Basic Information

Serial Number
97619090
Filing Date
October 4, 2022
Published for Opposition
January 24, 2023
Abandonment Date
October 23, 2023
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 23, 2023
Classes
005

Rights Holder

Cytokinetics, Incorporated

03
Address
350 Oyster Point Blvd
South San Francisco, CA 94080

Ownership History

Cytokinetics, Incorporated

Original Applicant
03
South San Francisco, CA

Cytokinetics, Incorporated

Owner at Publication
03
South San Francisco, CA

Legal Representation

Attorney
B. Brett Heavner

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

13 events
Date Code Type Description Documents
Oct 23, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Oct 23, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Mar 21, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 24, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 24, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 4, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 17, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 17, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 1, 2022 AMPX O PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Loading...
Dec 1, 2022 ALIE A ASSIGNED TO LIE Loading...
Oct 20, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 12, 2022 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Oct 7, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical preparations for human use, namely, medications to treat cardiovascular conditions; pharmaceutical preparations to treat hypertrophic cardiomyopathies, heart failure, and heart failure with preserved ejection fraction

Classification

International Classes
005